Yale Medicine School Cancer Center Study Explores New Path to Treat Advanced Triple-Negative Breast Cancer
February 03, 2022
February 03, 2022
NEW HAVEN, Connecticut, Feb. 3 (TNSJou) -- Yale School of Medicine issued the following news on Feb. 2, 2022:
A new study by researchers at Yale Cancer Center shows inhibition of the CECR2 gene prevents triple-negative breast cancer from advancing or metastasizing. The discovery is an early step in finding new therapeutics for triple-negative breast cancer (TNBC), one of the most difficult disease sub-types to treat. The findings are published online today in the journal Science Tra . . .
A new study by researchers at Yale Cancer Center shows inhibition of the CECR2 gene prevents triple-negative breast cancer from advancing or metastasizing. The discovery is an early step in finding new therapeutics for triple-negative breast cancer (TNBC), one of the most difficult disease sub-types to treat. The findings are published online today in the journal Science Tra . . .